Rapa Ida, Votta Arianna, Gatti Gaia, Izzo Stefania, Buono Nicola Lo, Giorgio Elisa, Vatrano Simona, Napoli Francesca, Scarpa Aldo, Scagliotti Giorgio, Papotti Mauro, Volante Marco
Department of Oncology at San Luigi Hospital, University of Turin, Turin, Italy.
Department of Medical Sciences, University of Turin, Turin, Italy.
Oncotarget. 2018 Jun 8;9(44):27535-27546. doi: 10.18632/oncotarget.25541.
Mammalian target of rapamycin (mTOR) is a promising therapeutic target in advanced lung carcinoid patients. However, the mechanisms of mTOR modulation and of responsiveness to mTOR inhibitors are largely unclear. Our aim was to analyze the expression and functional role of specific miRNAs in lung carcinoids as an alternative mechanism targeting mTOR pathway.
Seven miRNAs, selected by bioinformatic tools and literature search, were analyzed in 142 lung neuroendocrine neoplasms (92 carcinoids and a control group of 50 high grade neuroendocrine carcinomas), and compared with mTOR mRNA expression and clinical/pathological parameters. Tissue results were validated in two lung carcinoid cell lines by specific RNA interference and biological/pharmacological tests.
Tissutal expression of five miRNAs (miR-99b, miR-100, miR-155, miR-193a-3p, miR-193a-5p) was inversely correlated with mTOR mRNA expression, supporting their role in the negative regulation of mTOR transcription. High expression of miR-100, miR-193a-3p and miR-193a-5p was associated with aggressive features and, for the former two, with shorter time to progression. In H727 and UMC11 lung carcinoid cells, miR-100 modulated mTOR RNA and TORC1 complex protein expression, positively promoted cell migration and negatively influenced cell proliferation. Moreover, miR-100 directly influenced responsiveness of H727 and UMC11 cells to rapamycin.
MiR-100 actively participates to the regulation of mTOR expression in lung carcinoids and represents a novel candidate prognostic biomarker for this tumor type; moreover, inhibition of its expression is associated to increased responsiveness to mTOR inhibitors and might represent a novel strategy to sensitize lung carcinoids to these target agents.
雷帕霉素哺乳动物靶蛋白(mTOR)是晚期肺类癌患者一个有前景的治疗靶点。然而,mTOR调节机制以及对mTOR抑制剂的反应性在很大程度上尚不清楚。我们的目的是分析特定微小RNA(miRNA)在肺类癌中的表达及功能作用,作为靶向mTOR通路的另一种机制。
通过生物信息学工具和文献检索筛选出7种miRNA,在142例肺神经内分泌肿瘤(92例类癌和50例高级别神经内分泌癌组成的对照组)中进行分析,并与mTOR mRNA表达及临床/病理参数进行比较。通过特异性RNA干扰以及生物学/药理学试验在两种肺类癌细胞系中验证组织学结果。
5种miRNA(miR-99b、miR-100、miR-155、miR-193a-3p、miR-193a-5p)的组织表达与mTOR mRNA表达呈负相关,支持它们在mTOR转录负调控中的作用。miR-100、miR-193a-3p和miR-193a-5p的高表达与侵袭性特征相关,前两者还与较短的疾病进展时间相关。在H727和UMC11肺类癌细胞中,miR-100调节mTOR RNA和TORC1复合物蛋白表达,正向促进细胞迁移,负向影响细胞增殖。此外,miR-100直接影响H727和UMC11细胞对雷帕霉素的反应性。
MiR-100积极参与肺类癌中mTOR表达的调节,是这种肿瘤类型一种新的候选预后生物标志物;此外,抑制其表达与对mTOR抑制剂反应性增加相关,可能代表使肺类癌对这些靶向药物敏感的一种新策略。